You are here

Merck Serono S.A.

Project Leader(s): 

Dr. Fahima Nekka, Université de Montréal

Project team: 
Dr. Jun Li, Universite de Montreal
Dr. Catherine Litalien, Universite de Montreal
Dr. Anne-Laure Lepeyraque, Universite de Montreal
Dr. Pascal Girard, Merck Serono S.A.
Non-academic participants: 
Funding period: 
October 1, 2021 - March 31, 2021

When patients do not use medications as prescribed, the drugs may lose the ability to treat the disease. However, the impact of variations in patient use is not generally studied during clinical trials. By identifying the reasons for patient non-compliance and individual patient modifications, the team will determine the impact that poor compliance or dosing regimen adjustments have on therapeutic failure. A quantitative analysis of this impact will be developed. Initially, the team will focus on oral chemotherapy where concerns about compliance have become an important issue.